MONOPAR THERAPEUTICS INC. news, videos and press releases - Page 2
For more news please use our advanced search feature.
MONOPAR THERAPEUTICS INC. - More news...
MONOPAR THERAPEUTICS INC. - More news...
- Monopar to Participate in the Roth MKM 2023 Healthcare Opportunities Conference
- Monopar to Participate in the H.C. Wainwright 25th Annual Global Investment Conference
- Monopar Therapeutics Reports Second Quarter 2023 Financial Results and Recent Developments
- Monopar Provides Encouraging Camsirubicin Clinical Data Update
- Monopar Announces MNPR-101 Radiopharma Collaboration Agreement with National University of Singapore
- Monopar to Participate in the Radiopharma Forum by the Lake 2023
- Monopar to Participate in the Maxim Group’s Healthcare Virtual Conference
- Monopar Announces Encouraging Camsirubicin Phase 1b Trial Update
- Monopar Therapeutics Reports First Quarter 2023 Financial Results and Recent Developments
- Monopar to Present at the Jefferies Radiopharma Innovation Summit
- Monopar Announces Result of Interim Analysis of Phase 2b/3 VOICE Trial Evaluating Validive for Severe Oral Mucositis
- Monopar Therapeutics Reports Fourth Quarter and Full-Year 2022 Financial Results and Recent Developments
- Monopar to Present at the 35th Annual Roth Conference
- Monopar and NorthStar Announce Expanded Radiopharma Program, Positive Preclinical Results, and Visibility Toward Human Trials
- Monopar Announces Camsirubicin Clinical Program Update - Improved Side Effect Profile Seen to Date Compared to Doxorubicin
- Monopar Announces Projected Timeline of Upcoming Q1 2023 Data Events for Validive, Camsirubicin, and MNPR-101 RIT
- Monopar Announces Successful Advancement of Camsirubicin Phase 1b Clinical Trial Past Fourth Cohort, Escalates Next to 650mg/m2
- Monopar Announces Promising MNPR-202 Data from Ongoing National University of Singapore Collaboration
- Monopar Announces Encouraging Clinical Data from Ongoing Camsirubicin Phase 1b Trial
- Monopar Announces Timeline of Upcoming Data Events for Validive, Camsirubicin, and MNPR-202
- Monopar Announces Presentation Selected for 2022 American Society of Hematology (ASH) 64th Annual Meeting
- Monopar Announces Presentation Selected for 2022 Connective Tissue Oncology Society (CTOS) Annual Meeting
- Monopar Announces Completion of Phase 2b Enrollment and Commencement of Phase 3 Enrollment in its VOICE Trial for Severe Oral Mucositis
- Monopar to Present at Roth Inaugural Healthcare Opportunities Conference
- Monopar Therapeutics Reports Second Quarter 2022 Financial Results and Recent Program Developments
- Monopar Therapeutics Reports First Quarter 2022 Financial Results and Recent Program Developments
- Monopar Therapeutics Reports Fourth Quarter and Full-Year 2021 Financial Results and Recent Program Developments
- Monopar to Present at the 34th Annual Roth Conference and Maxim’s 2022 Virtual Growth Conference
- Monopar Announces Clinical and Preclinical Program Updates
- Monopar to Present at the H.C. Wainwright BioConnect Conference
